{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039809","form_type":"8-K","ticker":null,"cik":"0001804591","company_name":"Chrome Holding Co.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.314084+00:00","generated_at":"2026-06-12T02:33:56.289329+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"23andMe reports Q1 revenue down 6% to $61M, net loss widens; cuts 71 jobs (47% of Therapeutics); CTO retires","bullets":["Q1 FY2024 revenue $61M (down 6% YoY); net loss $105M vs $90M; Adj EBITDA deficit $50M (flat).","Workforce reduction of 71 employees (~11% total, 47% of Therapeutics) to save ~$15.5M annually; charges ~$3.8M.","CTO Dr. Kenneth Hillan retired Aug 8; will assist transition until Feb 8, 2024.","Cash $314M (down from $387M at Mar 31). FY2024 guidance: rev $255-275M; net loss $325-345M; Adj EBITDA deficit $160-180M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039809","json":"https://secwatch.observer/filing/0000950170-23-039809.json","markdown":"https://secwatch.observer/filing/0000950170-23-039809.md","text":"https://secwatch.observer/filing/0000950170-23-039809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1804591/000095017023039809/0000950170-23-039809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1804591/000095017023039809/me-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:33:56.289329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb1515edebff827a5eaeb5b2ffc5022fe0d65ffb","claim":"Chrome Holding Co. reported the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023 results: revenue $61 million, net income $105 million (Net loss). Guidance raised.","evidence_excerpt":"Total revenue for the three months ended June 30, 2023, was $61 million, compared to $65 million for the same period in the prior year, representing a decrease of 6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804591/000095017023039809/0000950170-23-039809-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023"},{"label":"Revenue","value":"$61 million"},{"label":"Net income","value":"$105 million (Net loss)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a1be470299","claim":"Dr. Kenneth Hillan retired as Chief Therapeutics Officer at Chrome Holding Co..","evidence_excerpt":"On August 2, 2023 (the “Notice Date”), Dr. Kenneth Hillan, Chief Therapeutics Officer of 23andMe Holding Co. (the “Company”), notified the Company of his decision to retire (the “Retirement”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804591/000095017023039809/0000950170-23-039809-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Therapeutics Officer"}],"fact_type":"executive_change"},{"claim_id":"b34f4092da0c12f86c5c87335a12e008ad487ca1","claim":"Chrome Holding Co. announced a restructuring with charges of approximately $3 million affecting Therapeutics segment (approximately 71 employees).","evidence_excerpt":"modification of certain stock options and restricted stock units (“equity compensation charges”). Severance and benefit continuation charges are estimated to be approximately $3 million and are expected to be recognized primarily in the second quarter of fiscal 2024, with the majority of such charges anticipated to be paid in cash during the same quarter. Equity","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804591/000095017023039809/0000950170-23-039809-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3 million"},{"label":"Affected area","value":"Therapeutics segment"},{"label":"Headcount","value":"approximately 71 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}